Benchmark Cuts Harvard Bioscience (NASDAQ:HBIO) Price Target to $4.50

Harvard Bioscience (NASDAQ:HBIO) had its price target trimmed by Benchmark from $5.50 to $4.50 in a research note published on Monday,Benzinga reports. The brokerage currently has a speculative buy rating on the medical instruments supplier’s stock.

Harvard Bioscience Price Performance

Shares of NASDAQ:HBIO opened at $0.61 on Monday. The company’s fifty day moving average is $1.20 and its 200 day moving average is $1.95. The company has a quick ratio of 0.91, a current ratio of 2.06 and a debt-to-equity ratio of 0.52. Harvard Bioscience has a 52 week low of $0.56 and a 52 week high of $4.70. The stock has a market cap of $26.93 million, a PE ratio of -1.85 and a beta of 1.46.

Institutional Trading of Harvard Bioscience

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Harvey Partners LLC grew its holdings in shares of Harvard Bioscience by 6.2% in the third quarter. Harvey Partners LLC now owns 2,715,000 shares of the medical instruments supplier’s stock worth $7,303,000 after purchasing an additional 157,500 shares during the last quarter. AMH Equity Ltd boosted its position in Harvard Bioscience by 4.7% during the 4th quarter. AMH Equity Ltd now owns 2,500,000 shares of the medical instruments supplier’s stock valued at $5,275,000 after buying an additional 111,132 shares during the period. Royce & Associates LP grew its holdings in Harvard Bioscience by 35.4% in the 4th quarter. Royce & Associates LP now owns 1,965,114 shares of the medical instruments supplier’s stock worth $4,146,000 after acquiring an additional 513,664 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Harvard Bioscience by 2.2% in the third quarter. Geode Capital Management LLC now owns 912,599 shares of the medical instruments supplier’s stock valued at $2,455,000 after acquiring an additional 19,972 shares during the period. Finally, State Street Corp raised its stake in shares of Harvard Bioscience by 1.1% during the third quarter. State Street Corp now owns 717,387 shares of the medical instruments supplier’s stock valued at $1,930,000 after acquiring an additional 7,763 shares during the last quarter. Institutional investors own 80.87% of the company’s stock.

Harvard Bioscience Company Profile

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.